top banner image  

topleft corner image     top right corner image
 


bullet

     top nav image

     

J Am Coll Cardiol Intv, 2008; 1:56-61, doi:10.1016/j.jcin.2007.11.004
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JACC Interventions
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Rogacka, R.
Right arrow Articles by Colombo, A.
PubMed
Right arrow Articles by Rogacka, R.
Right arrow Articles by Colombo, A.

Original Article

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation

Renata Rogacka, MD, Alaide Chieffo, MD, Iassen Michev, MD, Flavio Airoldi, MD, Azeem Latib, MD, John Cosgrave, MD, Matteo Montorfano, MD, Mauro Carlino, MD, Giuseppe M. Sangiorgi, MD, Alfredo Castelli, MD, Cosmo Godino, MD, Valeria Magni, MD, Tiziana C. Aranzulla, MD, Enrico Romagnoli, MD, Antonio Colombo, MD, FACC*

San Raffaele Scientific Institute and Emo Centro Cuore Columbus, Milan, Italy.

* Reprint requests and correspondence: Dr. Antonio Colombo, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. (Email: colombo.antonio{at}hsr.it).

Objectives: The purpose of this study was to evaluate the safety of dual antiplatelet therapy in patients in whom long-term anticoagulation (AC) with warfarin is recommended.

Background: The optimal antithrombotic strategy after percutaneous coronary intervention (PCI) for patients receiving AC is unclear.

Methods: Consecutive patients who underwent stent implantation and were discharged on triple therapy (defined as the combination of aspirin and thienopyridines and AC) were analyzed.

Results: Of the 127 patients with 224 lesions, 86.6% were men, with a mean age of 69.9 ± 8.8 years. Drug-eluting stents (DES) were positioned in 71 (55.9%), and bare-metal stents (BMS) were positioned in 56 (44.1%) patients. Atrial fibrillation (AF) was the main indication (59.1%) for AC treatment. The mean triple therapy duration was 5.6 ± 4.6 months, and clinical follow-up was 21.0 ± 19.8 months. During the triple therapy period, 6 patients (4.7%) developed major bleeding complications; 67% occurred within the first month. No significant differences between DES and BMS were observed in the incidence of major (5.6% vs. 3.6%, respectively, p = 1.0) and minor (1.4% vs. 3.6%, respectively, p = 0.57) bleeding and mortality (5.6% vs. 1.8%, respectively, p = 0.39). A significant difference was observed in favor of DES in target vessel revascularization (14.1% vs. 26.8%, p = 0.041).

Conclusions: While receiving triple therapy, major bleeding occurred in 4.7% of patients; one-half of the events were lethal, and most occurred within the first month.

Abbreviations and Acronyms
  AC = anticoagulation
  AF = atrial fibrillation
  BMS = bare-metal stent(s)
  INR = international normalized ratio
  MACCE = major adverse cardiac and cerebrovascular events
  MI = myocardial infarction
  PES = paclitaxel-eluting stent(s)
  SES = sirolimus-eluting stent(s)
  TLR = target lesion revascularization
  TVR = target vessel revascularization


Related articles in JACC Interventions:

Dual Antiplatelet and Oral Anticoagulant Therapy: Increasing Use and Precautions for a Hazardous Combination
Elaine M. Hylek and David E. Solarz
JACC Interventions 2008 1: 62-64. [Full Text]  



This article has been cited by other articles:


Home page
JWatch GeneralHome page
Hazards of Warfarin Plus Antiplatelet Therapy
Journal Watch (General), June 26, 2008; 2008(626): 2 - 2.
[Full Text]


Home page
Journal Watch CardiologyHome page
Risks of Combining Dual Antiplatelet Therapy with Warfarin
Journal Watch Cardiology, June 4, 2008; 2008(604): 3 - 3.
[Full Text]


Home page
J Am Coll Cardiol IntvHome page
J. M. Ruiz-Nodar, F. Marin, and G. Y.H. Lip
Antithrombotic Therapy Use After Percutaneous Coronary Intervention and Stent Implantation in Patients Taking Chronic Oral Anticoagulation
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 329 - 329.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
G. R. Giugliano and A. S. Lotfi
Dual Antiplatelet Therapy Plus Oral Anticoagulation: How Does Hemorrhagic Risk Impact Stent Selection?
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 330 - 330.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
R. Rogacka, A. Chieffo, and A. Colombo
Reply
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 330 - 331.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
E. M. Hylek and D. E. Solarz
Dual Antiplatelet and Oral Anticoagulant Therapy: Increasing Use and Precautions for a Hazardous Combination
J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 62 - 64.
[Full Text] [PDF]



 
   
 
home link current link search link archive link topics link cardiology careers link